Related Experiment Videos
[Clinical studies on cefprozil granules in pediatrics]
1Department of Pediatrics, Tokyo Ebara Municipal Hospital.
The Japanese Journal of Antibiotics
|November 1, 1992
Summary
Cefprozil (CFPZ) demonstrated high clinical efficacy and favorable pharmacokinetics in pediatric patients. This new oral cephalosporin showed a 92.7% efficacy rate with minimal side effects, making it a promising option for pediatric infections.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Clinical Pharmacy
Background:
- Cefprozil (CFPZ) is a novel oral cephalosporin antibiotic.
- Pediatric infections require effective and safe treatment options.
Purpose of the Study:
- To evaluate the clinical efficacy and pharmacokinetics of Cefprozil (CFPZ) in pediatric patients.
- To assess the safety profile of Cefprozil (CFPZ) in this population.
Main Methods:
- Pharmacokinetic study in 6 pediatric patients receiving single doses of 7.5 or 15.0 mg/kg.
- Clinical evaluation in 41 pediatric patients with various infections, treated with CFPZ (9.0-45.0 mg/kg daily for 3-14 days).
- Serum and urinary concentrations, peak serum concentrations, biological half-lives, and urinary recovery rates were determined.
Main Results:
- Peak serum concentrations of 2.13 and 6.22 µg/ml were observed at 2 hours for 7.5 and 15.0 mg/kg doses, respectively.
- Biological half-lives were 1.06 and 1.36 hours, with urinary recovery rates of 44.8% and 56.1%.
- An overall clinical efficacy rate of 92.7% was achieved across various infections, including tonsillitis and urinary tract infections. Bacterial eradication rate was 79.2%.
Conclusions:
- Cefprozil (CFPZ) exhibits favorable pharmacokinetic properties and high clinical efficacy in pediatric patients.
- The antibiotic demonstrated a good safety profile with no observed side effects, except for eosinophilia in two patients.
- Cefprozil (CFPZ) is a potentially valuable therapeutic agent for treating infections in children.